Antibody-dependent NK cell activation is associated with late kidney allograft dysfunction and the complement-independent alloreactive potential of donor-specific antibodies

Frontiers in Immunology

Volumn 7, Issue AUG, 2016, Pages

  Legris, Tristan ^a   Picard, Christophe ^b,c   Todorova, Dilyana ^d   Lyonnet, Luc ^a   Laporte, Cathy ^a   Dumoulin, Chloé ^a   Nicolino Brunet, Corinne ^a   Daniel, Laurent ^d   Loundou, Anderson ^e   Morange, Sophie ^a   Bataille, Stanislas ^a   Vacher Coponat, Henri ^a   Moal, Valérie ^a   Berland, Yvon ^a   Dignat George, Francoise ^a,d   Burtey, Stéphane ^a,d   Paul, Pascale ^a,d  

^a HÔPITAL DE LA CONCEPTION   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c AIX MARSEILLE UNIVERSITÉ   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Antibody dependent cellular cytotoxicity; Antibody mediated rejection; Donor specific antibodies; Kidney transplantation; Natural killer cells

Indexed keywords

ALLOANTIGEN; CD16 ANTIGEN; CD20 ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN G; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; ALLOIMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED REJECTION; ARTICLE; CELL ACTIVATION; CELLULAR HUMORAL ACTIVATION TEST; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMAPHERESIS; PROSPECTIVE STUDY; RENAL GRAFT DYSFUNCTION;

EID: 84989318860     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00288     Document Type: Article

References (60)

1. von Rossum A, Laher I, Choy JC. Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. Front Immunol (2014) 5:684. doi: 10.3389/fimmu.2014.00684
2. Sellares J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2012) 12:388-99. doi:10.1111/j.1600-6143.2011.03840.x
3. Walsh L, Dinavahi R. Current unmet needs in renal transplantation: a review of challenges and therapeutics. Front Biosci (Elite Ed) (2016) 8:1-14. doi:10.2741/746
4. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2009) 9:2520-31. doi:10.1111/j.1600-6143.2009.02799.x
5. Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int (2014) 85:258-64. doi:10.1038/ki.2013.300
6. Nguan C. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Urology (2013) 82:503-4. doi:10.1016/j.urology.2013.04.003
7. Nankivell BJ. Antibody-mediated vascular rejection: relation to causation. Lancet (2013) 381:275-7. doi:10.1016/S0140-6736(12)61577-3
8. Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen JP, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2013) 381:313-9. doi:10.1016/S0140-6736(12)61265-3
9. Hickey MJ, Valenzuela NM, Reed EF. Alloantibody generation and effector function following sensitization to human leukocyte antigen. Front Immunol (2016) 7:30. doi:10.3389/fimmu.2016.00030
10. Torres IB, Salcedo M, Moreso F, Sellares J, Castella E, Azancot MA, et al. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Clin Transplant (2014) 28:1148-54. doi:10.1111/ctr.12433
11. Hanf W, Bonder CS, Coates PT. Transplant glomerulopathy: the interaction of HLA antibodies and endothelium. J Immunol Res (2014) 2014:549315. doi:10.1155/2014/549315
12. Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 11:56-65. doi:10.1111/j.1600-6143.2010.03364.x
13. Bettinotti MP, Zachary AA, Leffell MS. Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 21(4):453-8. doi:10.1097/MOT.0000000000000326
14. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol (2015) 26(2):457-67. doi:10.1681/ASN.2013101144
15. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 369:1215-26. doi:10.1056/NEJMoa1302506
16. Tait BD, Susal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 95:19-47. doi:10.1097/TP.0b013e31827a19cc
17. Mujtaba MA, Goggins W, Lobashevsky A, Sharfuddin AA, Yaqub MS, Mishler DP, et al. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients. Clin Transplant (2011) 25:E96-102. doi:10.1111/j.1399-0012.2010.01341.x
18. Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, et al. Superiority of AbCross enzyme-linked immunosorbent assay cross-match over the B-cell complement-dependent lymphocytotoxicity cross-match. Transplant Proc (2013) 45:1383-5. doi:10.1016/j.transproceed.2013.01.039
19. Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, et al. Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival. J Am Soc Nephrol (2016) 27(2):615-25. doi:10.1681/ASN.2014040326
20. Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol (2012) 23:2061-71. doi:10.1681/ASN.2012070664
21. Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Horl WH, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant (2008) 8:2652-60. doi:10.1111/j.1600-6143.2008.02428.x
22. Hachem RR, Reinsmoen NL. What is the definition of a clinically relevant donor HLA-specific antibody (DSA)? Am J Transplant (2015) 15:299-300. doi:10.1111/ajt.13079
23. Frank R, Lal P, Kearns J, Molina MR, Wald JW, Goldberg LR, et al. Correlation of circulating complement-fixing donor-specific antibodies identified by the C1q assay and presence of C4d in endomyocardial biopsy specimens. Am J Clin Pathol (2016) 145:62-8. doi:10.1093/ajcp/aqv016
24. Strom TB, Tilney NL, Carpenter CB, Busch GJ. Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med (1975) 292:1257-63. doi:10.1056/NEJM197506122922402
25. Fishman JA. What's new and what's hot? Basic science at the American Transplant Congress 2012. Am J Transplant (2013) 13:275-80. doi:10.1111/ajt.12015
26. Bachelet T, Couzi L, Pitard V, Sicard X, Rigothier C, Lepreux S, et al. Cytomegalovirus-responsive gammadelta T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J Am Soc Nephrol (2014) 25(11):2471-82. doi:10.1681/ASN.2013101052
27. Crespo M, Yelamos J, Redondo D, Muntasell A, Perez-Saez MJ, Lopez-Montanes M, et al. Circulating NK-Cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. Am J Transplant (2015) 15:806-14. doi:10.1111/ajt.13010
28. Resch T, Fabritius C, Ebner S, Ritschl P, Kotsch K. The role of natural killer cells in humoral rejection. Transplantation (2015) 99:1335-40. doi:10.1097/TP.0000000000000757
29. Zhang ZX, Huang X, Jiang J, Lau A, Yin Z, Liu W, et al. Natural killer cells mediate long-term kidney allograft injury. Transplantation (2015) 99:916-24. doi:10.1097/TP.0000000000000665
30. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke CD, et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/-mice. Nat Med (2001) 7:557-62. doi:10.1038/87880
31. Farkash EA, Colvin RB. Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol (2012) 8:255-7. doi:10.1038/nrneph.2012.61
32. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant (2012) 12:313-21. doi:10.1111/j.1600-6143.2011.03836.x
33. Kohei N, Tanaka T, Tanabe K, Masumori N, Dvorina N, Valujskikh A, et al. Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts. Kidney Int (2016) 89:1293-306. doi:10.1016/j.kint.2016.02.030
34. Hidalgo LG, Sis B, Sellares J, Campbell PM, Mengel M, Einecke G, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant (2010) 10:1812-22. doi:10.1111/j.1600-6143.2010.03201.x
35. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant (2012) 12:1180-91. doi:10.1111/j.1600-6143.2011.03970.x
36. Loupy A, Lefaucheur C, Vernerey D, Chang J, Hidalgo LG, Beuscart T, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol (2014) 25:2267-77. doi:10.1681/ASN.2013111149
37. Gill RG. NK cells: elusive participants in transplantation immunity and tolerance. Curr Opin Immunol (2010) 22:649-54. doi:10.1016/j.coi.2010.09.005
38. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant (2015) 15:1336-48. doi:10.1111/ajt.13115
39. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, et al. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood (2012) 119:1418-27. doi:10.1182/blood-2011-06-363655
40. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood (2011) 118:3347-9. doi:10.1182/blood-2011-05-351411
41. Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc(gamma)RIIIa-158 V/V and V/F polymorphism. Blood (2007) 110:2561-4. doi:10.1182/blood-2007-01-070656
42. Shimizu S, Tanaka Y, Tazawa H, Verma S, Onoe T, Ishiyama K, et al. Fc-gamma receptor polymorphisms predispose patients to infectious complications after liver transplantation. Am J Transplant (2016) 16:625-33. doi:10.1111/ajt.13492
43. Neudoerfl C, Mueller BJ, Blume C, Daemen K, Stevanovic-Meyer M, Keil J, et al. The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol (2013) 4:46. doi:10.3389/fimmu.2013.00046
44. Vacher-Coponat H, Brunet C, Moal V, Loundou A, Bonnet E, Lyonnet L, et al. Tacrolimus/mycophenolate mofetil improved natural killer lymphocyte reconstitution one year after kidney transplant by reference to cyclosporine/azathioprine. Transplantation (2006) 82:558-66. doi:10.1097/01.tp.0000229390.01369.4a
45. Vacher-Coponat H, Brunet C, Lyonnet L, Bonnet E, Loundou A, Sampol J, et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant (2008) 23:1406-14. doi:10.1093/ndt/gfm596
46. Morteau O, Blundell S, Chakera A, Bennett S, Christou CM, Mason PD, et al. Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo. PLoS One (2010) 5:e13294. doi:10.1371/journal.pone.0013294
47. Hadaya K, de Rham C, Bandelier C, Ferrari-Lacraz S, Jendly S, Berney T, et al. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am J Transplant (2008) 8:2674-83. doi:10.1111/j.1600-6143.2008.02431.x
48. Shin BH, Ge S, Mirocha J, Karasyov A, Vo A, Jordan SC, et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. Transplantation (2014) 97:294-300. doi:10.1097/01.TP.0000438636.52085.50
49. Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. Transplantation (2012) 93:437-43. doi:10.1097/TP.0b013e31824215b7
50. Wettstein D, Opelz G, Susal C. HLA antibody screening in kidney transplantation: current guidelines. Langenbecks Arch Surg (2014) 399:415-20. doi:10.1007/s00423-013-1138-6
51. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 14:272-83. doi:10.1111/ajt.12590
52. Sis B, Jhangri GS, Riopel J, Chang J, de Freitas DG, Hidalgo L, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant (2012) 12:1168-79. doi:10.1111/j.1600-6143.2011.03931.x
53. Banasik M, Boratynska M, Koscielska-Kasprzak K, Kaminska D, Bartoszek D, Zabinska M, et al. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int (2014) 27:1029-38. doi:10.1111/tri.12371
54. Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, et al. Anti-CD20 therapy acts via FcgammaRIIIA to diminish responsiveness of human natural killer cells. Cancer Res (2015) 75:4097-108. doi:10.1158/0008-5472.CAN-15-0781
55. Sood P, Hariharan S. Transplantation: rituximab induction for prevention of HLA-antibody rebound. Nat Rev Nephrol (2014) 10:682-3. doi:10.1038/nrneph.2014.179
56. Rostaing L, Kamar N. Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Kidney Int (2014) 85:245-7. doi:10.1038/ki.2013.425
57. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 5:520. doi:10.3389/fimmu.2014.00520
58. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol (2014) 15:707-16. doi:10.1038/ni.2939
59. Kellner C, Derer S, Valerius T, Peipp M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods (2014) 65:105-13. doi:10.1016/j.ymeth.2013.06.036
60. Mishima Y, Terui Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, et al. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism. Int Immunol (2012) 24:477-83. doi:10.1093/intimm/dxs048